Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Tonix begins phase I study of TNX-601 for daytime treatment of PTSD

Sep. 5, 2019

Biogen explores non-covalent activation of NRF2 for neurodegenerative and other disorders

Sep. 4, 2019

Vulnerable brains can be steered towards healthy development

Sep. 4, 2019

Grunenthal and UniQuest establish neuropathic pain collaboration

Sep. 3, 2019

Suven evaluates SUVN-G3031 in phase II trial for narcolepsy with and without cataplexy

Sep. 3, 2019

TREM2 correlates with slow decline in AD

Sep. 3, 2019

Daiichi Sankyo presents new analgesics

Sep. 3, 2019

Eicosis' soluble epoxide hydrolase inhibitor EC-5026 to enter the clinic

Sep. 3, 2019

Alcohol consumption is deceased with FGFR1 inhibition in rodents

Sep. 3, 2019

New phase I trial to study gene therapy for APOE4 homozygotes with Alzheimer's disease

Sep. 2, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
‘Detargeted’ targeted gene therapy improves activity in Pompe
BioWorld
A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
Roche reports new TREM2 agonists
BioWorld Science
F. Hoffmann-la Roche Ltd. and Hoffmann-La Roche Inc. have identified new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for...
Genescience presents STAT6 degrader for atopic dermatitis
BioWorld Science
Genescience Pharmaceutical Co. Ltd. has presented data on a new STAT6 PROTAC degrader – GenSciP166 – which selectively targets STAT6 for proteasomal degradation....
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...